Julie Parsons, MD

Despite significant advancements in spinal muscular atrophy (SMA) management, unmet needs persist, especially for patients aged 2 and older without early treatment.

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration challenges, with key selection factors like patient age and gene copy number, according to Julie Parsons, MD, a professor and neurologist from the University of Colorado School of Medicine.